Oncology Pharmacotherapy and Applications of Biosimilars Program

Access to the OPAB Program ends December 31, 2023​​​​​​.

Recognizing that there is a rapid expansion of Biosimilars usage in clinical practice, and that the role of an oncology pharmacist is evolving and further integrating as a key member of a multidisciplinary healthcare team, ISOPP developed the Oncology Pharmacotherapy and Applications of Biosimilars (OPAB) online education program that supports oncology pharmacists to safely and confidently introduce Biosimilars into their clinical practice and multidisciplinary healthcare team.

ISOPP presents this education program in a novel way by giving both fundamentals and advanced aspects of 1) pharmacotherapy of various cancers, 2) implementation of biosimilars in oncology practice and 3) interpretation of available scientific and regulatory data and pharmacist’s recommendations for using biosimilars in different cancers.

The Oncology Pharmacotherapy and Applications of Biosimilars (OPAB) Program is supported by Pfizer through an educational grant.

The education program is for ISOPP and CSHP Members who are oncology pharmacists and have practiced for at least one year in the area of oncology pharmacy. Registration is complimentary for ISOPP members.

The program launched in October 2021 and consists of 10 online courses (total of 25 hours), supplemented by a Biosimilars Masterclass, which took place at ISOPP’s 2023 Symposium in Spain.


We acknowledge the Faculty members, Reviewers and Task Force members for their contributions to the OPAB Program.



This program is supported by an educational grant from Pfizer.


Accreditation for this program is provided by the California Society of Health-System Pharmacists (CSHP). CSHP is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.